{"id":60597,"date":"2026-03-23T16:17:34","date_gmt":"2026-03-23T08:17:34","guid":{"rendered":"https:\/\/flcube.com\/?p=60597"},"modified":"2026-03-23T16:17:35","modified_gmt":"2026-03-23T08:17:35","slug":"lepu-biopharma-wins-nmpa-approval-for-perioperative-hnscc-trial-first-in-world-egfr-adc-pd-1-combination-advances-to-clinic","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=60597","title":{"rendered":"Lepu Biopharma Wins NMPA Approval for Perioperative HNSCC Trial \u2013 First\u2011in\u2011World EGFR ADC + PD\u20111 Combination Advances to Clinic"},"content":{"rendered":"\n

Lepu Biopharma Co., Ltd.<\/strong> (HKG: 2157<\/a>) announced NMPA IND approval<\/strong> for a groundbreaking Phase II\/III clinical trial<\/strong> evaluating Becotatug Vedotin (MRG003)<\/strong> in combination with Pucotenlimab (HX008)<\/strong> for the perioperative treatment of locally advanced, resectable head and neck squamous cell carcinoma (HNSCC)<\/strong> \u2013 marking the world’s first study<\/strong> to explore an EGFR ADC + PD\u20111 monoclonal antibody combination<\/strong> in the curative\u2011intent, early\u2011stage setting<\/strong> vs. traditional late\u2011line metastatic therapy.<\/p>\n\n\n\n

Regulatory Milestone<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Agency<\/strong><\/td>NMPA (China)<\/td><\/tr>
Trial Status<\/strong><\/td>IND approved \u2013 clinical trial initiation authorized<\/td><\/tr>
Company<\/strong><\/td>Lepu Biopharma Co., Ltd. (HKG: 2157)<\/td><\/tr>
Combination<\/strong><\/td>Becotatug Vedotin (MRG003) + Pucotenlimab (HX008)<\/td><\/tr>
Indication<\/strong><\/td>Perioperative treatment of locally advanced, resectable HNSCC<\/td><\/tr>
Global Significance<\/strong><\/td>First study worldwide<\/strong> exploring EGFR ADC + PD\u20111 in perioperative HNSCC<\/td><\/tr>
Paradigm Shift<\/strong><\/td>From late\u2011line metastatic therapy to early\u2011stage perioperative intervention<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Product Profiles<\/h2>\n\n\n\n

Becotatug Vedotin (MRG003) \u2013 EGFR ADC<\/h3>\n\n\n\n
Component<\/th>Specification<\/th><\/tr><\/thead>
Target<\/strong><\/td>EGFR (epidermal growth factor receptor)<\/td><\/tr>
Payload<\/strong><\/td>MMAE<\/strong> (monomethyl auristatin E) \u2013 potent microtubule inhibitor<\/td><\/tr>
Linker<\/strong><\/td>Valine\u2011citrulline (cleavable)<\/td><\/tr>
Class<\/strong><\/td>Antibody\u2011drug conjugate (ADC)<\/td><\/tr>
Mechanism<\/strong><\/td>EGFR\u2011mediated tumor cell binding \u2192 endocytosis \u2192 lysosomal MMAE release \u2192 microtubule disruption \u2192 apoptosis<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Pucotenlimab (HX008) \u2013 PD\u20111 Inhibitor<\/h3>\n\n\n\n
Feature<\/th>Differentiation<\/th><\/tr><\/thead>
Target<\/strong><\/td>Human PD\u20111 (programmed cell death\u20111)<\/td><\/tr>
Design<\/strong><\/td>Humanized monoclonal antibody with differentiated Fc engineering<\/strong><\/td><\/tr>
Key Innovation<\/strong><\/td>High FcRn binding affinity<\/strong> \u2192 extended half\u2011life<\/strong><\/td><\/tr>
Clinical Benefit<\/strong><\/td>Enhanced efficacy + improved patient compliance (reduced dosing frequency)<\/td><\/tr>
Development Partnership<\/strong><\/td>Co\u2011developed and marketed by Hansoh Biotech + Lepu Biopharma<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Clinical Strategy & Trial Design<\/h2>\n\n\n\n
Dimension<\/th>Traditional HNSCC Approach<\/th>Lepu Biopharma Innovation<\/th><\/tr><\/thead>
Treatment Setting<\/strong><\/td>Late\u2011line: recurrent\/metastatic disease with limited curative options<\/td>Perioperative<\/strong>: neoadjuvant + adjuvant around definitive surgery<\/td><\/tr>
Therapeutic Goal<\/strong><\/td>Palliation; prolongation of survival<\/td>Cure\u2011intent<\/strong>: improve complete resection rates; reduce recurrence<\/td><\/tr>
Combination Rationale<\/strong><\/td>EGFR ADC (tumor\u2011specific cytotoxicity) + PD\u20111 (immune checkpoint modulation)<\/td>Dual mechanism targeting both tumor cell killing and anti\u2011tumor immunity<\/td><\/tr>
Global Uniqueness<\/strong><\/td>No prior EGFR ADC + PD\u20111 perioperative data<\/td>First\u2011in\u2011world<\/strong> exploration of this combination paradigm<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Market Impact & Outlook<\/h2>\n\n\n\n